NASDAQ:DXCM - Nasdaq - US2521311074 - Common Stock - Currency: USD
NASDAQ:DXCM (2/21/2025, 10:17:55 AM)
88.7075
-0.63 (-0.71%)
The current stock price of DXCM is 88.7075 USD. In the past month the price increased by 2.58%. In the past year, price decreased by -23.15%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.75 | 232.89B | ||
ISRG | INTUITIVE SURGICAL INC | 82.5 | 215.67B | ||
BSX | BOSTON SCIENTIFIC CORP | 42.06 | 155.59B | ||
SYK | STRYKER CORP | 31.71 | 147.34B | ||
MDT | MEDTRONIC PLC | 16.86 | 115.43B | ||
BDX | BECTON DICKINSON AND CO | 16.44 | 65.66B | ||
EW | EDWARDS LIFESCIENCES CORP | 28.34 | 43.80B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.33 | 41.70B | ||
IDXX | IDEXX LABORATORIES INC | 40.82 | 37.61B | ||
RMD | RESMED INC | 26.37 | 34.23B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 17.29 | 23.72B | ||
STE | STERIS PLC | 23.94 | 21.60B |
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 9,600 full-time employees. The company went IPO on 2005-04-14. The firm enables people to take real-time control of health through continuous glucose monitoring (CGM) systems. The firm is engaged in diabetes care technology. Based on the needs of users, caregivers, and providers, the Company works to simplify and improve diabetes management around the world. The firm is primarily focused on the design, development, and commercialization of CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Dexcom Stelo is designed specifically for people with type II diabetes who do not use insulin and are not at risk for hypoglycemia. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device.
DEXCOM INC
6340 Sequence Dr
San Diego CALIFORNIA 92121 US
CEO: Kevin R. Sayer
Employees: 9550
Company Website: https://www.dexcom.com/
Investor Relations: https://investors.dexcom.com
Phone: 18582000200
The current stock price of DXCM is 88.7075 USD. The price decreased by -0.71% in the last trading session.
The exchange symbol of DEXCOM INC is DXCM and it is listed on the Nasdaq exchange.
DXCM stock is listed on the Nasdaq exchange.
32 analysts have analysed DXCM and the average price target is 104.35 USD. This implies a price increase of 17.63% is expected in the next year compared to the current price of 88.7075. Check the DEXCOM INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
DEXCOM INC (DXCM) has a market capitalization of 34.65B USD. This makes DXCM a Large Cap stock.
DEXCOM INC (DXCM) currently has 9550 employees.
DEXCOM INC (DXCM) has a support level at 84.66 and a resistance level at 89.35. Check the full technical report for a detailed analysis of DXCM support and resistance levels.
The Revenue of DEXCOM INC (DXCM) is expected to grow by 14.43% in the next year. Check the estimates tab for more information on the DXCM EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
DXCM does not pay a dividend.
DEXCOM INC (DXCM) will report earnings on 2025-04-23, after the market close.
The PE ratio for DEXCOM INC (DXCM) is 53.76. This is based on the reported non-GAAP earnings per share of 1.65 and the current share price of 88.7075 USD. Check the full fundamental report for a full analysis of the valuation metrics for DXCM.
The outstanding short interest for DEXCOM INC (DXCM) is 2.53% of its float. Check the ownership tab for more information on the DXCM short interest.
ChartMill assigns a technical rating of 7 / 10 to DXCM. When comparing the yearly performance of all stocks, DXCM is a bad performer in the overall market: 61.51% of all stocks are doing better.
ChartMill assigns a fundamental rating of 7 / 10 to DXCM. While DXCM has a great profitability rating, there are some minor concerns on its financial health.
Over the last trailing twelve months DXCM reported a non-GAAP Earnings per Share(EPS) of 1.65. The EPS increased by 9.27% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 14.29% | ||
ROA | 8.89% | ||
ROE | 27.4% | ||
Debt/Equity | 0.62 |
ChartMill assigns a Buy % Consensus number of 86% to DXCM. The Buy consensus is the average rating of analysts ratings from 32 analysts.
For the next year, analysts expect an EPS growth of 24.7% and a revenue growth 14.43% for DXCM